{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:16:12Z","timestamp":1777270572399,"version":"3.51.4"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Clinical development of immune checkpoint inhibitors targeting the PD-1 pathway has led to clinical benefits for patients with multiple solid tumor and hematologic malignancies and has revolutionized modern oncology. High response rates to PD-1 blockade in patients with classical Hodgkin lymphoma and certain subtypes of non-Hodgkin lymphoma highlight an intrinsic biologic sensitivity to this strategy of treatment. Despite early success of checkpoint inhibitor and immunomodulatory drug combinations in phase 2 studies in multiple myeloma, safety concerns in patients treated with the combination of immunomodulatory drugs and checkpoint inhibitors in myeloma have stalled drug development in this space. Novel combination approaches exploring PD-1 inhibitors with epigenetic modifiers in leukemia are underway.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000297","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T16:31:33Z","timestamp":1516725093000},"page":"31-35","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Development of PD-1 Blockade in Hematologic Malignancies"],"prefix":"10.1097","volume":"24","author":[{"given":"Matthew J.","family":"Pianko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","first-page":"280 sr1","article-title":"On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation","volume":"7","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","year":"2002","journal-title":"Nat Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"bib4-20230924","first-page":"409","article-title":"Blockade of the B7-H1\/PD-1 pathway for cancer immunotherapy","volume":"84","year":"2011","journal-title":"Yale J Biol Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","year":"2011","journal-title":"Nat Immunol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","year":"2003","journal-title":"Nat Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","article-title":"Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1\/PD-1 interactions","volume":"69","year":"2009","journal-title":"Cancer Res"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.4049\/jimmunol.178.9.5552","article-title":"Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells","volume":"178","year":"2007","journal-title":"J Immunol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced PD-L1\/B7-H1 expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","year":"2014","journal-title":"Eur J Haematol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","year":"2017","journal-title":"Cell Rep"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","year":"2016","journal-title":"J Hematol Oncol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (pts) with relapsed or refractory classical hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039)","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V128.22.1108.1108","article-title":"Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","year":"2014","journal-title":"Clin Neuropathol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of PD-L1 in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","year":"2016","journal-title":"Virchows Arch"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of PD-L1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble PD-L1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib32-20230924","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","year":"2015","journal-title":"Blood Cancer J"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood.V126.23.2661.2661","article-title":"The exhausted intratumoral T cell population in B-cell non-Hodgkin lymphoma is defined by LAG-3, PD-1 and Tim-3 expression","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/jlb.66.6.981","article-title":"Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes","volume":"66","year":"1999","journal-title":"J Leukoc Biol"},{"key":"bib37-20230924","first-page":"52","article-title":"Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma","volume":"20","year":"1996","journal-title":"Cancer Detect Prev"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood.V85.9.2521.bloodjournal8592521","article-title":"Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells","volume":"85","year":"1995","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/intimm\/6.8.1177","article-title":"Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells","volume":"6","year":"1994","journal-title":"Int Immunol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","year":"2006","journal-title":"J Exp Med"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4 + CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(\u2212)CD8(\u2212)alphabetaTCR(+) double negative t cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","year":"2009","journal-title":"Br J Haematol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1983.tb02021.x","article-title":"Abnormal monoclonal antibody-defined helper\/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage","volume":"53","year":"1983","journal-title":"Br J Haematol"},{"key":"bib46-20230924","first-page":"ra46","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","year":"2012","journal-title":"Sci Signal"},{"key":"bib47-20230924","article-title":"Facts and hopes in immunotherapy of lymphoma and myeloma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","year":"2017","journal-title":"Blood Cancer J"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1189\/jlb.0708446","article-title":"Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4","volume":"85","year":"2009","journal-title":"J Leukoc Biol"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.exphem.2006.03.006","article-title":"The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans","volume":"34","year":"2006","journal-title":"Exp Hematol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1038\/bcj.2014.50","article-title":"The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity","volume":"4","year":"2014","journal-title":"Blood Cancer J"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","year":"2015","journal-title":"Cell"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","year":"2015","journal-title":"Cell"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS)","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.immuni.2015.12.008","article-title":"The PD-1 Axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation","volume":"44","year":"2016","journal-title":"Immunity"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2010-04-283119","article-title":"PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1172\/JCI39165","article-title":"Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice","volume":"120","year":"2010","journal-title":"J Clin Invest"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/bmt.2017.69","article-title":"Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma","volume":"52","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201801000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:12:04Z","timestamp":1695532324000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201801000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000297","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}